Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: The atherosclerosis risk in communities (ARIC) study

Circulation

Volumn 98, Issue 3, 1998, Pages 204-210

  Folsom, Aaron R ^a   Nieto, F Javier ^c   McGovern, Paul G ^a   Tsai, Michael Y ^b   Malinow, M René ^d   Eckfeldt, John H ^b   Hess, David L ^d   Davis, C E ^e  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Coronary disease; Homocysteine; Polymorphism (genetics); Vitamins

Indexed keywords

CYSTATHIONINE BETA SYNTHASE; HOMOCYSTEINE; METHYLENETETRAHYDROFOLATE DEHYDROGENASE; PYRIDOXAL 5 PHOSPHATE; VITAMIN B GROUP;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CORONARY ARTERY DISEASE; DIET SUPPLEMENTATION; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; HOMOCYSTINURIA; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR;

EID: 0032555167     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.98.3.204     Document Type: Article

References (51)

1. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocyst(e)ine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA. 1995;274: 1049-1057.
2. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D, Tishler PV, Hennekens CH. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA. 1992;268:877-881.
3. Arnesen E, Refsum H, Bønaa KH, Ueland PM, Førde OH, Nordrehaug JE. Serum total homocysteine and coronary heart disease. Int J Epidemiol. 1995;24:704-709.
4. Alfthan G, Pekkanen J, Jauhiainen M, Pitkäniemi J, Karvonen M, Tuomilehto J, Salonen JT, Ehnholm C. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis. 1994;106:9-19.
5. Weijenberg PM. Prospective Studies on Coronary Artery Disease in the Elderly: The Role of Classical and New Risk Factors [doctoral thesis]. Wageningen, the Netherlands: Agricultural University; 1996.
6. Evans RW, Shaten BJ, Hempel JD, Cutler JA, Kuller LH, for the MRFIT Research Group. Homocyst(e)ine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial. Arterioscler Thromb Vasc Biol. 1997;17:1947-1953.
7. 6 and risk of myocardial infarction in US physicians. J Am Coll Nutr. 1996;15:136-143.
8. Verhoef P, Hennekens CH, Allen RH, Stabler SP, Willett WC, Stampfer MJ. Plasma total homocysteine and risk of angina pectoris with subsequent coronary artery bypass surgery. Am J Cardiol. 1997;79:799-801.
9. Morrison HI, Schaubel D, Desmeules M, Wigle DT. Serum folate and risk of fatal coronary heart disease. JAMA. 1996;275:1893-1896.
10. Ma J, Stampfer MJ, Hennekens CH, Frosst P, Selhub J, Horsford J, Malinow MR, Willett WC, Rozen R. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. Circulation. 1996;94:2410-2416.
11. 6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA. 1998;279:359-364.
12. The ARIC Investigators. The Atherosclerosis Risk in Communities (ARIC) study: design and objectives. Am J Epidemiol. 1989;129: 687-702.
13. Baecke JAH, Burema J, Frijters JER. A short questionnaire for the measurement of habitual physical activity in epidemiological studies. Am J Clin Nutr. 1982;36:936-942.
14. Bond MG, Barnes R, Riley WA, Wilmoth SK, Chambless LE, Howard G, Owens B. High resolution B-mode ultrasound scanning methods in the Atherosclerosis Risk in Communities study (ARIC). J Neuroimaging. 1991;1:68-73.
15. Riley WA, Barnes R, Bond MG, Evans GW, Chambless L, Heiss G. High resolution B-mode ultrasound reading methods in the Atherosclerosis Risk in Communities study (ARIC). J Neuroimaging. 1991;1:168-172.
16. Rose GA, Blackburn H, Gillum RF, Prineas RJ. Cardiovascular Survey Methods. 2nd ed. Basel, Switzerland: World Health Organization; 1982. WHO Monograph Series 56.
17. Willett WC, Sampson L, Stampfer MJ, Rosner B, Bain C, Witschi J, Hennekens CH, Speizer FE. Reproducibility and validity of a semiquantitative food frequency questionnaire. Am J Epidemiol. 1985;122:51-65.
18. Siedel J, Hegele EO, Ziegenhom J, Wahlefeld AW. Reagent for the enzymatic determination of total serum cholesterol with improved lipolytic efficiency. Clin Chem. 1983;29:1075-1080.
19. Nagele U, Hagele EO, Sauer G, Wiedemann E, Lehmann P, Wahlefeld AW, Gruber W. Reagent for the enzymatic determination of serum total triglycerides with improved lipolytic efficiency. J Clin Chem Clin Biochem. 1984;22:165-174.
20. 2+ precipitation. Clin Chem. 1982;28:1574. Abstract.
21. Clauss A. Gerinnungsphysiologische Schnellmethode zur bestimmung des fibrinogens. Acta Haematol. 1957;17:237-246.
22. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
23. White AD, Folsom AR, Chambless LE, Sharrett AR, Yang K, Conwill D, Higgins M, Williams OD, Tyroler HA. Community surveillance of coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) study: methods and initial two years' experience. J Clin Epidemiol. 1996;49:223-233.
24. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988; 16:1215.
25. Smolin LA, Schneider JA. Measurement of total plasma cysteamine using high-performance liquid chromatography with electrochemical detection. Anal Biochem. 1988;168:374-379.
26. Malinow MR, Kang SS, Taylor LM, Wong PWK, Coull B, Inahara T, Mukerjee D, Sexton G, Upson B. Prevalence of hyperhomocyst(e)inemia in patients with peripheral arterial occlusive disease. Circulation. 1989; 79:1180-1188.
27. Malinow MR, Sexton G, Averbuch M, Grossman M, Wilson D, Upson G. Homocyst(e)inemia in daily practice: levels in coronary artery disease. Coron Artery Dis. 1990;1:215-220.
28. 919A mutations of the cystathionine β-synthase gene by single-strand conformational polymorphism. Clin Biochem. 1996;28:473-478.
29. Tsai MY, Bignell M, Schwichtenberg K, Hanson NQ. High prevalence of a mutation in the cystathionine β-synthase gene. Am J Hum Genet. 1996;59:1262-1267.
30. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJH, den Heijer M, Kluijtmans LAJ, van den Heuvel LP, Rozen R. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10:111-113.
31. Garber CE, Carleton RA, Heller GV. Comparison of "Rose Questionnaire Angina" to exercise thallium scintigraphy: different findings in males and females. J Clin Epidemiol. 1992;45:715-720.
32. Barlow WE. Robust variance estimation for the case-cohort design. Biometrics. 1994;50:1064-1072.
33. Malinow MR, Nieto FJ, Szklo M, Chambless LE, Bond G. Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults. Circulation. 1993;87:1107-1118.
34. Verhoef P, Kok FJ, Kruyssen DACM, Schouten EG, Witteman JCM, Grobbee DE, Ueland PM, Refsum H. Plasma total homocysteine, B vitamins, and risk of coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 1997;17:989-995.
35. Graham IM, Daly LE, Refsum HM, Robinson K, Brattström LE, Ueland PM, Palma-Reis RJ, Boers GHJ, Sheahan RG, Israelsson B, Uiterwaal CS, Meleady R, McMaster D, Verhoef P, Witteman J, Rubba P, Bellet H, Wautrecht JC, de Valk HW, Sales Lúis AC, Parrot-Roulaud FM, Tan KS, Higgins I, Garcon D, Medrano MJ, Candito M, Evans AE, Andria G, for The European Concerted Action Project. Plasma homocysteine as a risk factor for vascular disease. JAMA. 1997;277:1775-1781.
36. Landgren F, Israelsson B, Lindgren A, Hultberg B, Andersson A, Brattström L. Plasma homocysteine in acute myocardial infarction: homocysteine-lowering effect of folic acid. J Intern Med. 1995;237:381-388.
37. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Serum total homocysteine and coronary heart disease in middle-aged British men. Heart. 1996;75:53. Abstract.
38. Witteman BML, Hoes AW, Koudstaal PJ, Grobbee DE. Homocysteine and risk of cardiovascular disease in elderly: The Rotterdam Study. Can J Cardiol 1997;13(suppl B):150B. Abstract.
39. Woo KS, Chook P, Lolin YI, Cheung ASP, Chan LT, Sun YY, Sanderson JE, Metreweli C, Celermajer DS. Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans. Circulation. 1997;96:2542-2544.
40. Nygård O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SM. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med. 1997;337:230-236.
41. Robinson K, Mayer EL, Miller DP, Green R, van Lente F, Gupta A, Kottke-Marchant K, Savon SR, Selhub J, Nissen SE, Kutner M, Topol EJ, Jacobsen DW. Hyperhomocysteinemia and low pyridoxal phosphate: common and independent reversible risk factors for coronary artery disease. Circulation. 1995;92:2825-2830.
42. 6, pyridoxal phosphate, and folate. Am J Cardiol. 1995;75:1107-1111.
43. Verhoef P, Stampfer MJ, Buring JE, Gaziano JM, Allen RH, Stabler SP, Reynolds RD, Kok FJ, Hennekens CH, Willen WC. Homocysteine metabolism and risk of myocardial infarction: relationship with vitamins B6, B12, and folate. Am J Epidemiol. 1996;143:845-859.
44. 6: Its Role in Health and Disease. New York, NY: Alan R. Liss, Inc; 1985:337-346.
45. Schmitz C, Lindpaintner K, Verhoef P, Gaziano JM, Buring J. Genetic polymorphism of methylenetetrahydrofolate reductase and myocardial infarction: a case-control study. Circulation. 1996;94:1812-1814.
46. Deloughery TG, Evans A, Sadeghi A, McWilliams J, Henner WD, Taylor LM, Press RD. Common mutation in methylenetetrahydrofolate reductase: correlation with homocysteine metabolism and late-onset vascular disease. Circulation. 1996;94:3074-3078.
47. van Bockxmeer FM, Mamotte CDS, Vasikaran SD, Taylor RR. Methylenetetrahydrofolate reductase gene and coronary artery disease. Circulation. 1997;95:21-23.
48. Kang SS, Passen EL, Ruggie N, Wong PWK, Sora H. Thermolabile defect of methylenetetrahydrofolate reductase in coronary artery disease. Circulation. 1993;88:1463-1469.
49. Gallagher PM, Meleady R, Shields D, Tan KS, McMaster D, Rozen R, Evans A, Graham IM, Whitehead AS. Homocysteine and risk of premature coronary heart disease: evidence for a common gene mutation. Circulation. 1996;94:2154-2158.
50. Morita H, Taguchi J-I, Kurihara H, Kitaoka M, Kaneda H, Kurihara Y, Maemura K, Shindo T, Minamino T, Ohno M, Yamaoki K, Ogasawara K, Aizawa T, Suzuki S, Yazaki Y. Genetic polymorphism of 5,10-methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease. Circulation. 1997;95:2032-2036.
51. Tsai MY, Garg U, Key NS, Hanson NQ, Suh A, Schwichtenberg K. Molecular and biochemical approaches in the identification of heterozygotes for homocystinuria. Atherosclerosis. 1996;122:69-77.